| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy,* University of California, San Francisco, California; the Division of Microscopic Anatomy and Bio-Imaging, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan; the Department of Research Pharmacology, Pfizer Global Research and Development, San Diego, California; and Regeneron Pharmaceuticals, Tarrytown, New York
Angiogenesis inhibitors are receiving increased attention as cancer therapeutics, but little is known of the cellular effects of these inhibitors on tumor vessels. We sought to determine whether two agents, AG013736 and VEGF-Trap, that inhibit vascular endothelial growth factor (VEGF) signaling, merely stop angiogenesis or cause regression of existing tumor vessels. Here, we report that treatment with these inhibitors caused robust and early changes in endothelial cells, pericytes, and basement membrane of vessels in spontaneous islet-cell tumors of RIP-Tag2 transgenic mice and in subcutaneously implanted Lewis lung carcinomas. Strikingly, within 24 hours, endothelial fenestrations in RIP-Tag2 tumors disappeared, vascular sprouting was suppressed, and patency and blood flow ceased in some vessels. By 7 days, vascular density decreased more than 70%, and VEGFR-2 and VEGFR-3 expression was reduced in surviving endothelial cells. Vessels in Lewis lung tumors, which lacked endothelial fenestrations, showed less regression. In both tumors, pericytes did not degenerate to the same extent as endothelial cells, and those on surviving tumor vessels acquired a more normal phenotype. Vascular basement membrane persisted after endothelial cells degenerated, providing a ghost-like record of pretreatment vessel number and location and a potential scaffold for vessel regrowth. The potent anti-vascular action observed is evidence that VEGF signaling inhibitors do more than stop angiogenesis. Early loss of endothelial fenestrations in RIP-Tag2 tumors is a clue that vessel phenotype may be predictive of exceptional sensitivity to these inhibitors.
This article has been cited by other articles:
 |
|
 |
|
  P. BALUK and D. M. MCDONALD Markers for Microscopic Imaging of Lymphangiogenesis and Angiogenesis Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Raatschen, G. H. Simon, Y. Fu, B. Sennino, D. M. Shames, M. F. Wendland, D. M. McDonald, and R. C. Brasch Vascular Permeability during Antiangiogenesis Treatment: MR Imaging Assay Results as Biomarker for Subsequent Tumor Growth in Rats Radiology, May 1, 2008; 247(2): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alferez, R. W. Wilkinson, J. Watkins, R. Poulsom, N. Mandir, S. R. Wedge, I. T. Pyrah, N. R. Smith, L. Jackson, A. J. Ryan, et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice Mol. Cancer Ther., March 1, 2008; 7(3): 590 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, and P. A. D'Amore VEGF and TGF-{beta} are required for the maintenance of the choroid plexus and ependyma J. Exp. Med., February 18, 2008; 205(2): 491 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu, N. S. Holalkere, A. Muzikansky, K. Horgan, and D. V. Sahani Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma Oncologist, February 1, 2008; 13(2): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Marneros, H. She, H. Zambarakji, H. Hashizume, E. J. Connolly, I. Kim, E. S. Gragoudas, J. W. Miller, and B. R. Olsen Endogenous endostatin inhibits choroidal neovascularization FASEB J, December 1, 2007; 21(14): 3809 - 3818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al. Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade PNAS, November 20, 2007; 104(47): 18363 - 18370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Fenton and S. F. Paoni The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature Cancer Res., October 15, 2007; 67(20): 9921 - 9928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Baluk, J. Fuxe, H. Hashizume, T. Romano, E. Lashnits, S. Butz, D. Vestweber, M. Corada, C. Molendini, E. Dejana, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels J. Exp. Med., October 1, 2007; 204(10): 2349 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Duda, R. K. Jain, and C. G. Willett Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Smith, N. H. James, I. Oakley, A. Wainwright, C. Copley, J. Kendrew, L. M. Womersley, J. M. Jurgensmeier, S. R. Wedge, and S. T. Barry Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts Mol. Cancer Ther., August 1, 2007; 6(8): 2198 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Potikyan, R. O.V. Savene, J. M. Gaulden, K. A. France, Z. Zhou, E. S. Kleinerman, S. L. Lessnick, and C. T. Denny EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins Cancer Res., July 15, 2007; 67(14): 6675 - 6684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M.W. Verheul, H. Hammers, K. van Erp, Y. Wei, T. Sanni, B. Salumbides, D. Z. Qian, G. D. Yancopoulos, and R. Pili Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. George Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 753s - 757s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. von Degenfeld, A. Banfi, M. L. Springer, R. A. Wagner, J. Jacobi, C. R. Ozawa, M. J. Merchant, J. P. Cooke, and H. M. Blau Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia FASEB J, December 1, 2006; 20(14): 2657 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962 Clin. Cancer Res., December 1, 2006; 12(23): 6978 - 6984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ioannidou, K. Deinhardt, J. Miotla, J. Bradley, E. Cheung, S. Samuelsson, Y.-S. Ng, and D. T. Shima From the Cover: An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis PNAS, November 7, 2006; 103(45): 16770 - 16775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, L. Zhang, S. Meshinchi, C. Dias-Leme, D. Raffin, J. D. Johnson, M. K. Treutelaar, and C. F. Burant Islet Microvasculature in Islet Hyperplasia and Failure in a Model of Type 2 Diabetes Diabetes, November 1, 2006; 55(11): 2965 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Murphy, S. Makonnen, W. Lassoued, M. D. Feldman, C. Carter, and W. M.F. Lee Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006) Am. J. Pathol., November 1, 2006; 169(5): 1875 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Hall Review of the Pericyte during Angiogenesis and its Role in Cancer and Diabetic Retinopathy Toxicol Pathol, October 1, 2006; 34(6): 763 - 775. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Fraser, H. Wilson, C. Wulff, J. S Rudge, and S. J Wiegand Administration of vascular endothelial growth factor Trap during the 'post-angiogenic' period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction, October 1, 2006; 132(4): 589 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.A. Goodlad, A.J. Ryan, S.R. Wedge, I.T. Pyrah, D. Alferez, R. Poulsom, N.R. Smith, N. Mandir, A.J. Watkins, and R.W. Wilkinson Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer Carcinogenesis, October 1, 2006; 27(10): 2133 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions Oncologist, July 1, 2006; 11(7): 753 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Levi, A. S. Ghabrial, and M. A. Krasnow Drosophila talin and integrin genes are required for maintenance of tracheal terminal branches and luminal organization Development, June 15, 2006; 133(12): 2383 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Albert, P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R.-Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., April 1, 2006; 5(4): 995 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Guo, P. A. Marcotte, J. O. McCall, Y. Dai, L. J. Pease, M. R. Michaelides, S. K. Davidsen, and K. B. Glaser Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol. Cancer Ther., April 1, 2006; 5(4): 1007 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Tonra, D. S. Deevi, E. Corcoran, H. Li, S. Wang, F. E. Carrick, and D. J. Hicklin Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res., April 1, 2006; 12(7): 2197 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Yao, M. G. Ozawa, A. S. Varner, I. M. Kasman, Y. H. Chanthery, R. Pasqualini, W. Arap, and D. M. McDonald Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res., March 1, 2006; 66(5): 2639 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF]
|
|
|
|
|
|
T. Nakahara, S. M. Norberg, D. R. Shalinsky, D. D. Hu-Lowe, and D. M. McDonald Effect of Inhibition of Vascular Endothelial Growth Factor Signaling on Distribution of Extravasated Antibodies in Tumors Cancer Res., February 1, 2006; 66(3): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S.R. Maharaj, M. Saint-Geniez, A. E. Maldonado, and P. A. D'Amore Vascular Endothelial Growth Factor Localization in the Adult Am. J. Pathol., February 1, 2006; 168(2): 639 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Baffert, T. Le, G. Thurston, and D. M. McDonald Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H107 - H118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rabinovitch Cellular and Molecular Pathobiology of Pulmonary Hypertension Conference Summary Chest, December 1, 2005; 128(6_suppl): 642S - 646S. [Full Text] [PDF]
|
|
|
|
|
|
M. Rabinovitch Cellular and Molecular Pathobiology of Pulmonary Hypertension Conference Summary Chest, December 1, 2005; 128(6_suppl): 642S - 646S. [Full Text] [PDF]
|
|
|
|
|
|
D. M. McDonald and P. Baluk Imaging of Angiogenesis in Inflamed Airways and Tumors: Newly Formed Blood Vessels Are Not Alike and May Be Wildly Abnormal: Parker B. Francis Lecture Chest, December 1, 2005; 128(6_suppl): 602S - 608S. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Miller, S. Vosseler, N. Mirancea, D. J. Hicklin, P. Bohlen, H. E. Volcker, F. G. Holz, and N. E. Fusenig Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants Am. J. Pathol., November 1, 2005; 167(5): 1389 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. R. Kim, A. Yudina, J. Figueiredo, W. Reichardt, D. Hu-Lowe, A. Petrovsky, H. W. Kang, D. Torres, U. Mahmood, R. Weissleder, et al. Detection of Early Antiangiogenic Effects in Human Colon Adenocarcinoma Xenografts: In vivo Changes of Tumor Blood Volume in Response to Experimental VEGFR Tyrosine Kinase Inhibitor Cancer Res., October 15, 2005; 65(20): 9253 - 9260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Rugo, R. S. Herbst, G. Liu, J. W. Park, M. S. Kies, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich, J. L. Freddo, and G. Wilding Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results J. Clin. Oncol., August 20, 2005; 23(24): 5474 - 5483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Hou, D. Medynski, S. Wu, X. Lin, and L.-Y. Li VEGI-192, a New Isoform of TNFSF15, Specifically Eliminates Tumor Vascular Endothelial Cells and Suppresses Tumor Growth Clin. Cancer Res., August 1, 2005; 11(15): 5595 - 5602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. di Tomaso, D. Capen, A. Haskell, J. Hart, J. J. Logie, R. K. Jain, D. M. McDonald, R. Jones, and L. L. Munn Mosaic Tumor Vessels: Cellular Basis and Ultrastructure of Focal Regions Lacking Endothelial Cell Markers Cancer Res., July 1, 2005; 65(13): 5740 - 5749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Parsons-Wingerter, I. M. Kasman, S. Norberg, A. Magnussen, S. Zanivan, A. Rissone, P. Baluk, C. J. Favre, U. Jeffry, R. Murray, et al. Uniform Overexpression and Rapid Accessibility of {alpha}5{beta}1 Integrin on Blood Vessels in Tumors Am. J. Pathol., July 1, 2005; 167(1): 193 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Wedge, J. Kendrew, L. F. Hennequin, P. J. Valentine, S. T. Barry, S. R. Brave, N. R. Smith, N. H. James, M. Dukes, J. O. Curwen, et al. AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer Cancer Res., May 15, 2005; 65(10): 4389 - 4400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity Clin. Cancer Res., May 1, 2005; 11(9): 3514 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Magnussen, I. M. Kasman, S. Norberg, P. Baluk, R. Murray, and D. M. McDonald Rapid Access of Antibodies to {alpha}5{beta}1 Integrin Overexpressed on the Luminal Surface of Tumor Blood Vessels Cancer Res., April 1, 2005; 65(7): 2712 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sharma, N. R. Trivedi, M. A. Zimmerman, D. A. Tuveson, C. D. Smith, and G. P. Robertson Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors Cancer Res., March 15, 2005; 65(6): 2412 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Pauli, H. Tang, J. Wang, P. Bohlen, R. Posser, T. Hartman, M. V. Sauer, J. Kitajewski, and R. C. Zimmermann The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of Pregnancy in the Rodent Endocrinology, March 1, 2005; 146(3): 1301 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vosseler, N. Mirancea, P. Bohlen, M. M. Mueller, and N. E. Fusenig Angiogenesis Inhibition by Vascular Endothelial Growth Factor Receptor-2 Blockade Reduces Stromal Matrix Metalloproteinase Expression, Normalizes Stromal Tissue, and Reverts Epithelial Tumor Phenotype in Surface Heterotransplants Cancer Res., February 15, 2005; 65(4): 1294 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Baluk, C. G. Lee, H. Link, E. Ator, A. Haskell, J. A. Elias, and D. M. McDonald Regulated Angiogenesis and Vascular Regression in Mice Overexpressing Vascular Endothelial Growth Factor in Airways Am. J. Pathol., October 1, 2004; 165(4): 1071 - 1085. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
